Circulating Tumour DNA Is an Independent Prognostic Biomarker for Survival in Metastatic BRAF or NRAS-Mutated Melanoma Patients

Circulating tumour DNA (ctDNA) can be used to identify gene alterations. The purpose of this study was to determine whether the detection of ctDNA, based on the identification of BRAF and NRAS mutations before systemic treatment initiation, was associated with the prognosis of metastatic melanoma. I...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Cancers (Basel)
Egile Nagusiak: Herbreteau, Guillaume, Vallée, Audrey, Knol, Anne-Chantal, Théoleyre, Sandrine, Quéreux, Gaelle, Frénard, Cécile, Varey, Emilie, Hofman, Paul, Khammari, Amir, Dréno, Brigitte, Denis, Marc G.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: MDPI 2020
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7409003/
https://ncbi.nlm.nih.gov/pubmed/32664549
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers12071871
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak